Therefore, RORγt agonists may accelerate CCL20 production through signaling to Type 17 T cells to attract DC cells, resulting in an elevation of CXCL10 levels and immune CD8+ T cell infiltration in the tumor. The gene discussed is CD8A; the disease is neoplasm.